我们现在能治疗继发进展型多发性硬化症吗？
Can We Treat Secondary Progressive Multiple Sclerosis Now?
作者信息
Bhatia Rohit, Singh Nishita
机构信息
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Ann Indian Acad Neurol. 2019 Apr-Jun;22(2):131-136. doi: 10.4103/aian.AIAN_345_18.
Abstract
Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS.
摘要
继发进展型多发性硬化（SPMS）的特征是残疾持续累积且无间歇性恢复。由于对其发病机制了解有限且治疗选择较少，这些患者的治疗颇具挑战性。本文总结了SPMS试验在定义和实施方面的困难，回顾了SPMS已批准和未批准疗法的主要临床试验，最后介绍了正在研发用于SPMS的疗法。
相似文献
1
Can We Treat Secondary Progressive Multiple Sclerosis Now?我们现在能治疗继发进展型多发性硬化症吗？
Ann Indian Acad Neurol. 2019 Apr-Jun;22(2):131-136. doi: 10.4103/aian.AIAN_345_18.
2
Management of worsening multiple sclerosis with mitoxantrone: a review.米托蒽醌治疗病情进展型多发性硬化症的研究综述
Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013.
3
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌：其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
4
Disease-Modifying Treatment in Progressive Multiple Sclerosis.进展性多发性硬化症的疾病修正治疗
Curr Treat Options Neurol. 2018 Apr 7;20(5):12. doi: 10.1007/s11940-018-0496-3.
5
Management of secondary-progressive multiple sclerosis.继发进展型多发性硬化的管理
CNS Drugs. 2004;18(10):653-69. doi: 10.2165/00023210-200418100-00003.
6
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
7
Disease-modifying Therapies for Multiple Sclerosis.多发性硬化症的疾病修正疗法
Curr Treat Options Neurol. 2003 Jan;5(1):35-54. doi: 10.1007/s11940-003-0021-0.
8
Rehabilitation with neuromuscular electrical stimulation leads to functional gains in ambulation in patients with secondary progressive and primary progressive multiple sclerosis: a case series report.神经肌肉电刺激康复可使继发性进展和原发性进展多发性硬化症患者的步行功能得到改善：病例系列报告。
J Altern Complement Med. 2010 Dec;16(12):1343-9. doi: 10.1089/acm.2010.0080.
9
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.治疗继发进展型多发性硬化的药物干预策略。
Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0.
10
[Immunologic therapy for secondary and primary progressive multiple sclerosis].[继发性和原发性进行性多发性硬化症的免疫治疗]
Nihon Rinsho. 2003 Aug;61(8):1449-54.
引用本文的文献
1
The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.意大利不同表型多发性硬化症的流行病学、治疗模式及经济负担：复发缓解型多发性硬化症和继发进展型多发性硬化症
Clin Epidemiol. 2022 Nov 6;14:1327-1337. doi: 10.2147/CLEP.S376005. eCollection 2022.
2
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis.视网膜层变薄率作为多发性硬化进展性疾病转化的生物标志物。
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 13;9(6). doi: 10.1212/NXI.0000000000200030. Print 2022 Nov.
3
How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?参与EXPAND随机对照试验的继发进展型多发性硬化症患者与神经转导数据多发性硬化症登记处德国临床实践中的患者相比情况如何？
J Cent Nerv Syst Dis. 2022 Aug 4;14:11795735221115912. doi: 10.1177/11795735221115912. eCollection 2022.
4
Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies.定义良性/耗竭型多发性硬化症和停止疾病修正治疗。
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 8;8(2). doi: 10.1212/NXI.0000000000000960. Print 2021 Mar.
本文引用的文献
1
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.实践指南推荐摘要：多发性硬化症成人的疾病修正治疗：美国神经病学学会指南制定、传播和实施小组委员会的报告。
Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347.
2
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.西尼莫德治疗继发进展型多发性硬化症（EXPAND）的疗效：一项双盲、随机、3 期临床研究。
Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.
3
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.那他珠单抗治疗继发进展型多发性硬化症的疗效（ASCEND）：一项开放标签扩展的 3 期、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.
4
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.富马酸氯马斯汀作为多发性硬化症的髓鞘修复治疗（ReBUILD）：一项随机、对照、双盲、交叉试验。
Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.
5
Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.硫辛酸用于继发进展型多发性硬化症：一项随机对照试验。
Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e374. doi: 10.1212/NXI.0000000000000374. eCollection 2017 Sep.
6
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.多发性硬化症中的自体造血干细胞移植：一项荟萃分析。
Neurology. 2017 May 30;88(22):2115-2122. doi: 10.1212/WNL.0000000000003987. Epub 2017 Apr 28.
7
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.治疗继发进展型多发性硬化的药物干预策略。
Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0.
8
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.自体造血干细胞移植治疗复发缓解型多发性硬化症：与继发进展型多发性硬化症的比较。
Neurol Sci. 2017 Jul;38(7):1213-1221. doi: 10.1007/s10072-017-2933-6. Epub 2017 Apr 10.
9
Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.犬尿氨酸途径代谢组学可预测多发性硬化症的进展，并提供其发病机制的深入见解。
Sci Rep. 2017 Feb 3;7:41473. doi: 10.1038/srep41473.
10
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.环磷酰胺与甲泼尼龙治疗继发进展型多发性硬化的双盲对照随机试验
PLoS One. 2017 Jan 3;12(1):e0168834. doi: 10.1371/journal.pone.0168834. eCollection 2017.
Zotero 插件